Kornimate/medical-research-clean huggingface dataset:
f-18 altanserin pet study of patients receiving clozapine

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: to examine the feasibility of molecular imaging markers in clinical psychopharmacology

clinical evaluation of patients with psychiatric disorders is mainly dependent on patients' reports and clinicians' observations. in order to develop objective and quantifiable measures of psychopathology, molecular imaging techniques will be used in patients receiving clozapine.

Eligibility criteria:
inclusion criteria: * overtly healthy males as determined by medical history and physical examination * age from 19 to 45 years * weight ≥ 45 kg and within ± 20% of ibw * clinical laboratory test results within normal reference range for the national cancer center, hospital or results with minor deviations which are judged to be not clinically significant by the investigator * normal blood pressure and heart rate (supine and standing) as determined by the investigator * are reliable and willing to make themselves available for the duration of the study, and who will abide by the study restrictions * have given written informed consent exclusion criteria: * evidence of significant active hematologic disease * history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication * an episode of febrile disease or infectious disease within the past 2 weeks * evidence of significant active neuropsychiatric disease * regular use of drugs or abuse * history of drug hypersensitivity or clinically significant allergic reactions of any origin * participation in a study involving administration of an investigational compound within the past 30 days * use of any current medication * smoking history for recent 3 months

Keywords: clozapine pet schizophrenia schizoaffective disorder
selective neurectomy and mesh removal for chronic postherniotomy pain

Conditions: Pain

Summary: chronic postherniotomy pain affects every day activities in 5-8% of patients. however, no established treatment for this pain syndrome exists and previous reports on the effect of surgical intervention suffer from methodological problems. the neurophysiological characteristics suggest that pain arises from deeper neuronal structures injured during surgery or by ongoing inflammation from the mesh. this study investigates the effect of removing inserted mesh and compressed nerves on pain related daily impairment of activities assessed by the validated aas questionnaire before and 6 months after surgery


Eligibility criteria:
inclusion criteria: * adult ( more than 18 years old) patients with chronic pain after groin hernia surgery, and pain related impairment of everyday function. the pain should have occurred after previous open surgery. * the patient should be able to locate to a specific area with maximum pain. patients should be able to understand and use pain scales, and the aas-scale. exclusion criteria: * all that contradicts the above

Keywords: chronic pain groin hernia neuropathic pain chronic postoperative pain postherniotomy pain neuroplastic changes
the efficacy of brisement compared to physical therapy for the treatment of achilles tendinosis

Conditions: Achilles Tendinopathy

Summary: the purpose of this study is to compare the effectiveness of ultrasound guided brisement, brisement without ultrasound guidance and standard conservative treatment in patients who have been diagnosed with achilles tendinosis. we are asking you to take part in this research study because you are a patient of the brigham foot and ankle clinic who has been diagnosed with achilles tendinosis. about 100 people will take part in this research study, all at brigham and women's hospital (bwh). to our knowledge, there has been very little research in the efficacy of the addition of briesment injections to standard, conservative treatment of achilles tendinosis. we hope our results will show which method is the most effective conservative treatment for achilles tendinosis. this information will help doctors make decisions in the future.


Eligibility criteria:
inclusion criteria: * all patients enrolled in the study must have a diagnosis of achilles tendinosis with at least 2 weeks of pain at the distal achilles tendon which is typically worsened with activity. only cases of non-insertional achilles tendinosis (tendinosis occurring above the point of tendon insertion) will be included. exclusion criteria: * patients with a prior achilles tendon tear, chronic inflammatory disease, or history of posterior calf surgery will be excluded from the study. additionally, patients with prior injuries or fractures to the ankle and hind foot (talus and calcaneus) requiring surgery will be excluded.
community participation transition after stroke

Conditions: Stroke

Summary: stroke is one of the most serious, disabling health conditions in the united states. patients who undergo rehabilitation treatment for stroke have a high rate of disability. poor outcomes for many persons with stroke may be low because of incomplete treatment. the investigators will conduct a randomized controlled trial and a process evaluation to examine the feasibility, safety, and preliminary efficacy of an enhanced rehabilitation transition program, community participation transition after stroke (compass), designed to bridge inpatient rehabilitation and the home to support the performance of everyday activities.

we propose an enhanced rehabilitation transition program: community participation transition after stroke (compass) is a compensatory intervention consisting of one pre-discharge and five post-discharge home visits by an occupational therapist to supplement usual care. this intervention is focused on resolving barriers to independence in daily activities and participation using environmental support and active practice of daily activities in an individual's real home (versus an idealized clinical setting). this is a new combination of evidence-based compensatory treatments delivered in a novel treatment setting (transition to home). our long-term goal is the development of an effective intervention for a transition home designed to prevent excess disability for people living with stroke that could have an immediate effect and high public health significance.16 we will recruit 40 patients currently undergoing inpatient rehabilitation (ir) for ischemic stroke from longitudinal studies of stroke at washington university school of medicine (wusm) and randomize them to receive six additional sessions of the enhanced rehabilitation transition program or attention control. exploratory participation outcomes will be assessed by blinded evaluators at baseline, 6 months, 9 months, and 12 months after stroke. we will test the central hypothesis that compass will be acceptable, feasible, and superior to attention control on measures of participation and daily activity performance at 6 months after stroke.

Eligibility criteria:
inclusion criteria: 1. ≥45 years old 2. acute ischemic stroke, verified by a neurologist 3. baseline national institutes of health stroke scale (nihss) ≥8 4. independent in activities of daily living prior to stroke (premorbid rankin score of ≤2) 5. plan to discharge to home exclusion criteria: 1. severe terminal systemic disease that limits life expectancy to \<6 months 2. previous disorder (e.g., dementia) that makes interpretation of the self-rated scales difficult or a short blessed test (sbt) score of ≥9 (indicating significant cognitive impairment) 3. moderate to severe aphasia, as determined by the nihss best language rating of ≥2 4. residence in a congregate living facility 5. not eligible for a therapeutic pass

Keywords: stroke rehabilitation barriers to independence environmental support
fibrin glue after esd for high risk patients of bleeding

Conditions: Early Gastric Cancer; Gastric Adenoma

Summary: it is a prospective randomized controlled study to look for effectiveness of fibrin glue to prevent bleeding in high-risk patients after endoscopic submucosal dissection in gastric neoplasm.

investigators want to observe the bleeding rate after endoscopic submucosal dissection for gastric tumors in the high-risk group of bleeding (the size of the iatrogenic ulcer is expected to be 40mm or more, or taking aspirin, antiplatelet drugs, and anticoagulants). after resection and hemostasis with esd, fibrin glue (greenplast q™) is applied to the iatrogenic ulcer at the end of the procedure, and the control group will not be applied. after that, observe whether there is a difference in the bleeding rate within 48 hours and 4 weeks.

Eligibility criteria:
inclusion criteria: * ecog performance status 0-1 * patients scheduled to undergo esd due to gastric tumor (dysplasia, early gastric cancer) * patients who are expected to have an iatrogenic ulcer size of 40mm or more after endoscopic submucosal dissection, or are taking aspirin, antiplatelet drugs, or anticoagulants * patients who show adequate patient compliance and have adequate geographic distance for follow-up observation. exclusion criteria: * patients with sensitivity to cow protein or its derived ingredients * patients who had previously undergone partial gastrectomy * patients with early gastric cancer at the site previously undergoing esd * patients with clinically significant cardiopulmonary disease * patients with active hepatitis, liver disease that is not well controlled by treatment, or severe liver disorder * patients with severe renal impairment * patients with severe bone marrow dysfunction * patients with severe blood clotting impairment (including hemophilia) * patients with serious neurological or mental illness (e.g. epilepsy or dementia) * patients with reported side effects of contrast media * pregnant and lactating women * patients who have not obtained the informed consent of the patient and guardian * patients who are inadequate for clinical trials as judged by the attending physician
depression outpatient cardiology screening study

Conditions: Depression; Coronary Heart Disease

Summary: this study compares the effects of depression screening and case management to usual care in cardiology outpatients with documented evidence of coronary heart disease. despite strong evidence that depression is a risk factor for cardiac events, there is insufficient evidence to support the use of depression screening in cardiac patients.

depression and cardiovascular disease are highly comorbid, and depression is a risk factor for psychosocial morbidity, poor adherence to medical treatment regimens, physical inactivity, poor physical functioning, and medical morbidity and mortality in cardiac patients, especially following an acute coronary syndrome (acs). the american heart association recently recommended that all cardiac patients be screened for depression in order to improve identification and treatment of this risk factor. patients are screened for depression during an outpatient cardiology visit and those that screen positive will be contacted for enrollment into this study. patients are then randomized to receive collaborative care involving the patient, the patient's primary care physician (pcp), the cardiologist and the nurse case manager, or usual care (the patient is informed he/she screened positive for depression and is advised to contact their pcp and/or cardiologist). the pcp and/or cardiologist are free to evaluate, treat and refer that patient to mental health services as they deem necessary. patients in both groups will be monitored for depression severity and duration at 3, 6 and 12 months after enrollment. the course of their depression since enrollment or last follow-up includes remissions, new onsets, relapses, recurrences, and treatment will be determined.

Eligibility criteria:
inclusion criteria: * recent history of acute coronary syndrome or other cardiac event or documented heart disease * score of 10 or higher on the patient health questionnaire exclusion criteria: * suicidal ideation or behavior * cognitive impairment or inability to read or speak english * schizophrenia, bipolar disorder * active substance abuse or alcoholism * severe valvular disease, severe congestive heart failure, malignancy * physical limitations that would interfere with participation in the study * medical contraindications to the use of available antidepressants * participation in a competing research protocol * physician or patient refusal
intraoperative continuous lidocaine infusion in laparoscopic liver surgery

Conditions: Postoperative Pain After Laparoscopic Liver Resection

Summary: the goal of this clinical trial is to learn about effect of intraoperative continuous lidocaine infusion on postoperative pain, gut function and insulin resistance in patients undergoing laparoscopic liver surgery in adults. it will also learn about the safety of this infusion in this setting. the main questions it aims to answer are: does the intraoperative continuous systemic lidocaine infusion lower the opioid consumption 24h after surgery? is the time to first flatus after surgery reduced? is there increases in insulin resistance after intraoperative lidocaine infusion? researchers will compare intraoperative continuous systemic lidocaine infusion to a placebo (a look-alike substance that contains no drug, which will be normal saline administered at the same volume, infusion rate and timing) to see if intraoperative continuous systemic lidocaine infusion reduces postoperative pain after laparoscopic liver resection. participants will receive intraoperative continuous systemic lidocaine infusion or placebo. clinical assessment will be based on gathering data of nrs scores after the surgery, time to first flatus or stool. how much opioids the patients need in the first 3 postoperative days. laboratory assessment will include the evaluation of fasting blood glucose concentration and insulin levels preoperatively and on 1, 2 and 3 postoperative days.


Eligibility criteria:
inclusion criteria: * age \>18 years old * patients scheduled for laparoscopic liver surgery * patients classified as american society of anesthesiology (asa) physical status i- iii exclusion criteria: * medical history of seizure disorders * allergy to lidocaine * cardiac rhythm disorders (e.g. sick sinus syndrome, adams-stockes syndrome, ii- and iii-degree av blocks, double- bundle branch block, hr \< 50/min) * systolic heart failure (ejection fraction \<50%) * hepatic dysfunction (aspartate aminotransferase or alanine transaminase or total bilirubin \>2.5 times the upper limit of normal) * renal impairment (gfr \< 50ml/min/1.73 m2) * weight less than 45 kg, bmi \> 30 * metastases occurring in other distant organs * recent use of any analgesic medication within 48h before surgery * history of alcohol or substance abuse * chronic pain syndrome * chronic opioid use * inability to comprehend nrs or complete questionnaires due to language barrier or cognitive impairment

Keywords: postoperative pain laparoscopic liver surgery lidocaine infusion
evaluation of the philips respironics bipap autosv devices in subjects with sleep disorders

Conditions: Sleep Disordered Breathing; Sleep Apnea, Central

Summary: comparing two bipap autosv devices in participants with complex sleep apnea and determining if the new device will treat those participants no worse than when compared to its predecessor device.

the use of the bipap autosv4 device in participants with complex sleep apnea syndrome will treat those participants no worse than when compared to its predecessor device, the bipap autosv advanced™, with respect to: • apnea-hypopnea index (ahi)

Eligibility criteria:
inclusion criteria: * age 21-80 * ability to provide consent * documentation of medical stability by investigator * subjects who currently have been on positive airway pressure (pap) therapy for ≥ 4 weeks and who previously had a continuous positive airway pressure (cpap) titration with cai ≥ 5. or subjects who currently have been on pap therapy for ≥ 4 weeks and who had a diagnostic study done, with a cai ≥ 5, and were prescribed pap therapy without a cpap titration. * agreement to undergo a full-night, in-lab research cpap titration * agreement to undergo two full-night, in-lab therapy research polysomnography (psg) on bipap autosv devices exclusion criteria: * major medical or psychiatric condition that would interfere with the demands of the study, adherence to positive airway pressure, or the ability to complete the study. for example, unstable congestive heart failure, chronic lung disease, neuromuscular disease, daytime hypercapnia, cancer, or renal failure. * systolic blood pressure \< 80 mm hg at baseline visit. * participants in whom pap therapy is otherwise medically contraindicated. * participants who are unwilling to wear cpap * currently prescribed oxygen therapy (as needed, nocturnal, or continuous * participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (paco2 ≥ 45mmhg). * participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days. * participants with untreated, non-obstructive sleep apnea (osa)/ complex sleep apnea (csa) sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (plm arousal index \> 15).
impact of walking practice on persons with pd

Conditions: Parkinson's Disease

Summary: the purpose of this study is to investigate the impact of a specifically designed leg brace on walking endurance in individuals with parkinson's disease.

this is a randomized, repeated measures, matched group study. there will be three groups of participants, 20 participants per group, 60 participants total. group one (g1) will receive custom-fabricated bilateral braces and a standardized home walking/exercise program. group two (g2) will receive an off-the shelf ankle support and standardized home walking/exercise program. group three (g3) will receive the standardized walking/exercise program without any brace or afo. subjects will be randomized upon enrollment in the study. subjects will be followed for one year during this study and outcome measures will be collected 3 times over the course of the study. subjects will be seen every 6 months for the duration of the study for testing as well as for other visits as noted in the table below.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of parkinson's disease according to the uk brain bank criteria.5 2. age between 30 and 90. 3. ability to walk 150 feet independently over level surfaces with or without an assistive device. 4. hoehn and yahr stage 1-4. 5. less than 10 full heel raises in single limb stance bilaterally. 6. adequate insurance/funding to pay for physical therapy evaluation and afo devices. exclusion criteria: 1. body mass index greater than 40. 2. passive dorsiflexion range of motion less than approximately neutral (90 degrees) 3. any other uncontrolled health condition for which gait training is contraindicated

Keywords: gait parkinson's disease
electrodermabrasion compared to dermabrasion

Conditions: Scar

Summary: the purpose of this study is to determine if electrodermabrasion improves the cosmetic appearance of raise or bumpy scars or scars that are a different color or texture than the surrounding skin resulting from dermatologic surgery and whether it is as good as to the already used method of dermabrasion.


Eligibility criteria:
inclusion criteria: * not incarcerated * no mental impairments that could potentially interfere with the subject's ability to understand the various scar revision modalities and their potential risks and benefits, and thereby ability to provide informed consent * no bleeding disorders * a patient at uc davis medical center's department of dermatology who has undergone a dermatologic surgery procedure and is not satisfied with the appearance of his/her scar exclusion criteria: * incarcerated * with mental impairment(s) that could potentially interfere with subject's ability to understand the various scare revision modalities and their potential risks and benefits, and thereby ability to provide informed consent * with a bleeding disorder * with any other contraindication to the treatment used in the study * not a patient at uc davis medical center's department of dermatology * subjects who are not willing or able to return for follow-up assessments * subjects who are not able to give informed consent to enter the study * subjects who are not willing to complete the visual analog scale following treatment
this is a post approval study of coaptite® in the treatment of female urinary incontinence

Conditions: Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency

Summary: this is a post approval study of coaptite® in the treatment of female urinary incontinence.


Eligibility criteria:
inclusion criteria: * has female stress urinary incontinence that is due to intrinsic sphincter deficiency * has a baseline pad weight of greater than or equal to 50 grams * has viable mucosal lining at likely site of injection (bladder neck) * is at least 18 years of age * understands and accepts the obligation and is logistically able to present for all scheduled study visits * signs written informed consent exclusion criteria: * has had a previous treatment for urinary incontinence with a urethral bulking agent other than coaptite® or collagen * has detrusor instability * has bladder neuropathy * has nocturnal enuresis (bed wetting) * has grade ii or iii prolapsed bladder * has overflow or functional incontinence * has significant history of urinary tract infections without resolution * has current or acute conditions of cystitis or urethritis * has history of significant pelvic irradiation * is pregnant or lactating
perioperative thoracotomy analgesia; different analgesic modalities

Conditions: Analgesia

Summary: the study aim is to compare the analgesic effect of thoracic epidural versus serratus plane block versus erector spinae block in thoracic surgeries

comparing the analgesic effect of thoracic epidural versus serratus plane block versus erector spinae block in thoracic surgeries regarding pain control and possible side effects

Eligibility criteria:
inclusion criteria: * patients scheduled for thoracotomy age 18-65 exclusion criteria: * patient refusal coagulation defects abnormal kidney or liver functions local infection at site of block bone metastases